Open AccessCurrent status of adjuvant systemic therapy for primary breast cancer: Progress and controversy
Author(s) -
Hortobagyi Gabriel N.,
Buzdar Aman U.
Publication year - 1995
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/canjclin.45.4.199
Subject(s) - systemic therapy , medicine , breast cancer , adjuvant , adjuvant therapy , oncology , systemic disease , disease , cancer , intensive care medicine
Results from studies of adjuvant systemic therapy for primary breast cancer accumulated over the past 20 years have clearly established that this treatment approach improves disease-free and overall survival rates in high-risk patients. As a result, adjuvant systemic therapy has become an integral component of the modern, multimodality approach to management of primary breast cancer. However, controversies about the most effective approaches remain, and research continues. This article reviews the current status of adjuvant systemic therapy for primary breast cancer and discusses areas of persistent controversy.